• Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page

What's next?

What's next is: the days of showing up with samples, lunch and a canned message are gone. No one cares about you and your doll. BI is slow to learn this. Future pharma brings much more value or they won't survive the landscape of health care. As reps, we need to evolve our skills and abilities.
 




What's next is: the days of showing up with samples, lunch and a canned message are gone. No one cares about you and your doll. BI is slow to learn this. Future pharma brings much more value or they won't survive the landscape of health care. As reps, we need to evolve our skills and abilities.

Preach
 
























For those that are NOT afraid, maybe you should be. Has anyone seen that a new study was just reported about...that Farxiga has shown to reduce HF in patients WITHOUT diabetes! They have a better a better a1c reduction and it sounds like it will be a better CV indication so where does that leave Jardiance?

https://www.bloomberg.com/news/arti...xiga-lowers-death-risk-in-heart-failure-study

At the top of the market share and sales!! Farxiga will never beat Jardiance again and the HF data for Jardiance will smother this data